{"title": "Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines", "doi": "10.1101/2020.01.29.924100", "citation_id": "2020.01.29.924100v1", "date": "2020-01-29", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.01.29.924100", "abstract": "<h3>Abstract</h3>\n<p>Starting from December 2019, a novel coronavirus, named 2019-nCoV, was found to cause Severe Acute Respiratory (SARI) symptoms and rapid pandemic in China. With the hope to identify candidate drugs for 2019-nCoV, we adopted a computational approach to screen for available commercial medicines which may function as inhibitors for the M<sup>pro</sup> of 2019-nCoV. Up to 10 commercial medicines that may form hydrogen bounds to key residues within the binding pocket of 2019-nCoV M<sup>pro</sup> were identified, which may have higher mutation tolerance than lopinavir/ritonavir and may also function as inhibitors for other coronaviruses with similar M<sup>pro</sup> binding sites and pocket structures.</p>", "twitter_description": "Starting from December 2019, a novel coronavirus, named 2019-nCoV, was found to cause Severe Acute Respiratory (SARI) symptoms and rapid pandemic in China. With the hope to identify candidate drugs for 2019-nCoV, we adopted a computational approach to screen for available commercial medicines which may function as inhibitors for the Mpro of 2019-nCoV. Up to 10 commercial medicines that may form hydrogen bounds to key residues within the binding pocket of 2019-nCoV Mpro were identified, which may have higher mutation tolerance than lopinavir/ritonavir and may also function as inhibitors for other coronaviruses with similar Mpro binding sites and pocket structures.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.01.29.924100v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.01.29.924100v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.01.29.924100v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/01/29/2020.01.29.924100.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.01.29.924100v1", "access_rights": "restricted", "authors": ["Xin Liu", "Xiu-Jie Wang"]}